Answers are grounded in this paper and cite their sources.
Sir, Relapsing polychondritis (RP) is a very rare disease characterized by recurrent inflammation and cartilage destruction [1]. Although the pathogenesis remains to be determined, autoimmune reactions to antigens present in cartilages, such as type II collagen and matrilin, are thought to evoke symptoms. In addition to corticosteroids, immunosuppressive or cytotoxic drugs are used to treat the disease but acute involvement of the laryngotracheal cartilages causes airway destruction and cases which are resistant to these treatments have poor prognosis [1]. It has recently been reported that biological modifiers including anti-TNF-α and IL-1 receptor antagonist, can ameliorate symptoms associated with RP [2–7]. Since serum IL-6 levels were elevated in both our patients, who responded poorly to conventional therapies, administration of a humanized anti-IL-6 receptor antibody, tocilizumab [8], was initiated. A 29-yr-old female, diagnosed with RP because of auricular chondritis, nasal chondritis, costochondral pain and thickenings of the laryngotracheal walls, was admitted due to sudden dyspnoea in July 2005. After tracheotomy, treatment with prednisolone (40 mg/day) was started. Immunosuppressive drugs, such as cyclosporin, tacrolimus or cyclophosphamide, were not effective and treatment with infliximab (3 mg/kg), an anti-TNF-α antibody, was initiated from May 2006 with MTX (10 mg/week) and led to a reduction in CRP. When prednisolone was reduced, CRP became elevated and worsening of symptoms was observed. CT scan revealed severe airway narrowing and bronchial wall thickening (Fig. 1A) irrespective of eight injections of infliximab. Since serum IL-6 was elevated (19 pg/ml), informed consent and ethics committee approval were obtained for the injection of tocilizumab at 8 mg/kg monthly starting from June 2007. Nine months later, symptoms had markedly improved and the visual analogue scales (0–10) of subjective symptoms, such as auricular pain, nasal pain, costochondral pain, chest discomfort feeling and the amount of sputum were reduced, respectively, from 5 to 3, 5 to 2, 5 to 3, 5 to 1 and 5 to1. The CRP value remained below 0.04 mg/dl and serum MMP3 decreased from 215 to 64–155 ng/ml. One year after treatment the airway narrowing of bronchus had improved (Fig. 1B), resulting in reduction of prednisolone from 15 mg/day to 10 mg/day. Clinical course of two cases of RP. The administration of tocilizumab was started at day 0. Changes of doses of prednisolone (PSL) and MTX, and of serum levels of CRP, serum amyloid A (SAA) and MMP3 are shown. CT of the chest of Case 1 showed that severe airway narrowing and bronchial wall thickenings were observed (A). The tocilizumab treatment ameliorated the airway narrowing of bronchus (B). A 52-yr-old male with a past history of scleritis was admitted in March 2006 due to dyspnoea and polyarthritis. CT scan revealed severe airway narrowing. Ga-citrate scintigraphy showed a marked uptake for costochondral lesions, laryngotracheal walls and knee and shoulder joints, and serum autoantibody to type II collagen was elevated (2476 U/ml), leading to a diagnosis of RP. After tracheotomy, pulse intravenous methylprednisolone and oral administration of prednisolone (30 mg/day) was started. Subsequently, treatment with prednisolone (15–30 mg/day) and MTX (7.5–10 mg/week) kept the disease activity relatively stable with CRP of 0.2–1.4 mg/dl, but it was difficult to reduce the prednisolone dose below 15 mg/day. In September 2007, disease relapse occurred in association with exacerbation of wheezing, polyarthralgia and CRP elevation. Since at this time the respective serum concentrations of TNF-α, IL-6 and IL-1β were <5, 29.5 and <10 pg/ml, informed consent and ethics committee approval were obtained for the tocilizumab therapy at 8 mg/kg monthly starting from September 2007. CRP normalized and joint pains disappeared. MMP3 gradually decreased from 783–1080 ng/ml to 364–621 ng/ml, serum amyloid A also decreased from 24–89 to 7–11mg/l and after 5 months the titre of autoantibody to type II collagen had become 748 U/ml. The patient remained free of respiratory symptoms and polyarthralgia, which made it possible to reduce the prednisolone dose from 15 mg/day to 10 mg/day. RP, with a course varying from mild to fulminating, is a progressive disease. Depending on the severity, NSAIDs, corticosteroids and immunosuppressive or cytotoxic drugs including AZA, MTX, HCQ, colchicine, cyclophosphamide and cyclosporin have been used [1]. Recently the use of biological drugs, including infliximab, etanercept, adalimumab or anakinra, for RP cases that are resistant to these conventional treatments, have been reported to be effective for amelioration of the symptoms of this disease [2–7]. Examination of serum cytokine and chemokine profiles for RP showed that levels of MCP-1 (monocyte chemotactic protein-1), MIP-1β (macrophage inflammatory protein-1β) and IL-8 were much higher in patients with active RP than in controls but the IL-6 and TNF-α concentrations in RP appeared elevated but were not significantly elevated [9]. In our cases, conventional treatments failed to induce remission and tracheotomy was required for laryngotracheal stenosis. In the female patient, infliximab administration partially suppressed the disease activity but not completely. Since the IL-6 concentrations in the sera of both patients were elevated, tocilizumab treatment was initiated. After 9 months, clinical symptoms of both patients markedly improved, accompanied by normalization of CRP and reduction of MMP3. In the female patient, tocilizumab treatment resulted in improvement in airway narrowing and bronchial thickening. Tocilizumab was also effective as a steroid-sparing agent. The cases presented here thus indicate the potential value of anti-IL-6 receptor treatment for RP. Funding: This work was supported by the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation. Disclosure statement: T.K. holds a patent for tocilizumab. All other authors have declared no conflicts of interest.
No takes yet. Share an insight, caveat, or question.
Kawai et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: